Perspectives in Drug Therapy of HIV Infection

  title={Perspectives in Drug Therapy of HIV Infection},
  author={Janet H. Darbyshire},
SummaryCurrent key issues in the drug therapy of HIV infection include the timing of treatment initiation, the use of multiple-drug therapy and the duration of treatment. Although most clinicians agree that symptomatic HIV disease should be treated, there is no consensus as to whether patients should be treated before symptoms develop; the results of the Concorde trial failed to demonstrate any long term improvement in disease progression or survival when antiretroviral therapy was initiated in… 
Virtual Screening Models for Prediction of HIV-1 RT Associated RNase H Inhibition
Flexible docking experiments is the model of choice in terms of best retrieval of active from inactive compounds and efficiency and efficacy schemes and shape similarity, machine learning and FLAP models could also be used for further validation or filtration in virtual screening processes.
Structure-guided approach identifies a novel class of HIV-1 ribonuclease H inhibitors: binding mode insights through magnesium complexation and site-directed mutagenesis studies.
A structure-guided screening is coupled with a similarity-based search on the Specs database to identify a new class of HIV-1 RNase H inhibitors, and site-directed mutagenesis studies provide valuable insight into the binding mode of newly identified compounds.
The Role of Social Research in the Fight Against HIV/AIDS in Brazil and South Africa, 1990s-2010s. An Assessment of the Socio-Political Context of Knowledge Production and Use
The core argument of the present work is articulated in four points. First, social- science knowledge is crucial to understand and combat HIV/AIDS; second, integrated and engaged social-science is
Brazilian scientific production on pharmaceutical care from 1990 to 2009
Despite the limited quantity of articles, an increase in their number as well as in their scope and quality is expected, so as to create further knowledge that contributes to the recognition of pharmacists' actions by patient healthcare teams.


Evaluation of the quality of life associated with zidovudine treatment in asymptomatic human immunodeficiency virus infection. The AIDS Clinical Trials Group.
For asymptomatic patients treated with 500 mg of zidovudine, a reduction in the quality of life due to severe side effects of therapy approximately equals the increase in thequality of life associated with a delay in the progression of HIV disease.
Didanosine Compared with Continuation of Zidovudine in HIV-infected Patients with Signs of Clinical Deterioration While Receiving Zidovudine
The present trial examined the benefit of the clinical practice of switching from zidovudine to alternate therapy when patients manifest signs of progressive disease, such as new clinical syndromes or a marked decrease in CD4 counts.
A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group.
Changing treatment from zidovudine to 500 mg per day of didanosine appears to slow the progression of HIV disease.
A randomized pilot study of alternating or simultaneous zidovudine and didanosine therapy in patients with symptomatic human immunodeficiency virus infection.
While toxicities were generally mild and comparable between the regimens, 1 patient on the simultaneous regimen died of pancreatitis and lactic acidosis, indicating that simultaneous therapy provided more sustained elevations in CD4 cells than alternating therapy over 1 year.
Results of long term follow - up of a double blind study of ddI vs continued AZT among individuals with CD 4 s 200 - 500 / mm 3 [ abstract 358 B ]
    Coordinating Committee. Concorde: MRC/ANS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection
    • 1994